Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 173,877

Document Document Title
WO/2018/127733A1
Provided are peptide nucleic acid derivatives targeting a 3' splice site of the human SNAP25 pre-mRNA. The peptide nucleic acid derivatives potently induce at least a splice variant of the human SNAP25 mRNA in cells, and are useful to sa...  
WO/2018/129474A1
The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions ...  
WO/2018/127494A1
The present invention relates to novel bicyclic antimicrobial lanthipeptides, their corresponding peptide leader sequences, and the production thereof.  
WO/2018/129058A1
Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of t...  
WO/2018/129511A2
The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration an...  
WO/2018/127532A1
The present invention relates to microbial lysozyme, compositions comprising such and uses thereof.  
WO/2018/129200A2
In certain embodiments novel PAC1 receptor agonists are provided wherein the agonists comprise a targeting sequence that binds to the PAC1 receptor and said targeting sequence is attached to an amino acid sequence comprising a fragment o...  
WO/2018/128805A1
This disclosure relates to methods and materials for treating functional dyspepsia (FD). Specifically, the disclosure provides a method for treating FD in a mammal, wherein said method comprising administering a composition comprising se...  
WO/2018/128931A1
Provided is a pharmaceutical composition, including an antigen fusion protein which includes an antigen and an antagonist of an Fc gamma receptor. Also provided is a method of enhancing immunogenicity of an antigen, including conjugating...  
WO/2018/127917A1
PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 ami...  
WO/2018/129078A1
The disclosure provides methods and compositions that are useful to lessen and/or cure bacterial biofilms and treat diseases or disorders associated with biofilms using one or more novel polypeptide vaccines, antibodies, antibody fragmen...  
WO/2018/128587A1
Disclosed is an isolated variant of SMCHD1 peptide, or fragment thereof, comprising one or more mutation(s) that increases SMCHD1 activity in a cell compared to a cell with a wild- etype SMCHD1 peptide. Also disclosed are isolated nuclei...  
WO/2018/127493A1
The present invention relates to novel antimicrobial compounds and their uses, in particular as medicament, disinfectant, preservative or phytosanitary agent.  
WO/2018/129421A1
The purpose of this study and report was to evaluate GM6 as a Parkinson's Disease (PD) drug candidate and the possible mechanism of action and pathways. We show that GM6 rescues in vitro survival of salsolinol-treated SH-SY5Y cells and r...  
WO/2018/127914A1
The present invention provides compositions and methods for the treatment of Sjogren's syndrome (SS) and SS-related symptoms in human subjects by synthetic peptides based on the sequence of CDR1 of an anti-DNA monoclonal antibody.  
WO/2018/129506A2
The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration an...  
WO/2018/127582A2
The present invention relates to a new formulation of the oligonucleotide of SEQ ID NO:1.  
WO/2018/127828A1
The present invention relates to a therapeutic method using a tolerogenic peptide. In particular, the invention relates to a dosage regimen fora tolerogenic peptide. The therapeutic method can be used to treat or prevent conditions assoc...  
WO/2018/127830A1
The present invention relates to a composition which comprises peptides derived from S- Arrestin (retinal arrestin, S-antigen, S-Ag). The composition or peptides may be useful in the prevention and/or suppression of S-Ag autoimmunity, wh...  
WO/2018/128974A1
A method includes fluorescence imaging a cell that synthesizes Type 1 collagen. The cell includes a first gene encoding collagen a1(I) tagged with a first fluorescent tag and a second gene encoding collagen a2(I) tagged with a second flu...  
WO/2018/129099A2
A composition for treating cutaneous condition is provided and has 0.001-1.000 wt. % Aloe Barbadensis Leaf Juice, 1.000-40.000 wt. % Cyclopentasiloxane and Dimethicone Crosspolymer, 0.50-15.000 wt. % Dimethicone, 1.00-10.000 wt. % Ethoxy...  
WO/2018/129268A1
Provided herein are methods and related compositions for administering viral vectors and synthetic nanocarriers comprising an immunosuppressant. In some embodiments, the methods and compositions provided herein achieve improved transgene...  
WO/2018/126306A1
The present invention describes a pharmaceutical composition of biologically active peptides, associated with a controlled-release system using cyclodextrins or derivatives thereof, liposomes and biodegradable polymers and/or mixtures of...  
WO/2018/129463A1
Disclosed herein are methods of treating bacterial infection using a combination of minocycline and colistin to reduce the likelihood of acute kidney injury.  
WO/2018/129171A1
Disclosed are peptides capable of enzymatically-induced self-assembly to which is conjugated a redox modulator. These peptides are enzymatically responsive hydrogelators, and they can be used to form pericellular hydrogels/nanofibrils up...  
WO/2018/127916A1
PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino a...  
WO/2018/127829A1
The present invention relates to a composition comprising a peptide derived from myelin basic protein (MBP) peptide for use in treating or preventing uveitis in a subject  
WO/2018/128826A1
Compositions and methods for the treatment of bacterial infections include conjugates containing an Fc domain covalently linked to one or more monomers of cyclic heptapeptides or one or more dimers of cyclic heptapeptides. In particular,...  
WO/2018/128745A1
Provided are ciliary neurotrophic factor receptor (CNTFR) ligands. In certain aspects, a CNTFR ligand of the present disclosure exhibits increased affinity for CNTFR relative to the corresponding wild-type CNTFR ligand. In certain aspect...  
WO/2018/127918A1
SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha- CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein...  
WO/2018/129101A2
This invention describes methods for treating wound healing pathologies, inhibiting or reversing fibrotic skin disorders, including but not limited to keloids, atrophic and hypertrophic scars, and reversing skin aging via generating new ...  
WO/2018/129470A1
Methods and compositions are provided for the therapeutic use of hedgehog agents, for enhancing bone growth and regeneration in diabetic or pre-diabetic patients, including repair following injury, osseointegration of implants, and the l...  
WO/2018/127545A1
Dislcosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformd cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aerugin...  
WO/2018/129270A1
Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express ...  
WO/2018/128412A1
The present invention relates to: a fusion peptide comprising a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide; and a use thereof and, more specifically, to: a fusion peptide in which a thrombus-targeting peptid...  
WO/2018/127919A1
SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion pro...  
WO/2018/129384A1
Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein incl...  
WO/2018/127920A1
Methods of treating Fabry disease via administration of stabilized plant recombinant human alpha galactosidase protein comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety, and ...  
WO/2018/127363A1
Present invention relates to a composition for use in the treatment of arthritides. Alkaline phosphatase (AP), an ectophosphatase with an anti-inflammatory and barrier protecting mechanism of action shows potent anti-rheumatoid arthritis...  
WO/2018/127792A1
A method for creating a consolidated compound for delivering an immunomodulatory and imiquimod to a patient, comprising diluting immunomodulator extract to a desired dilution by transferring a desired quantity of the concentrated immunom...  
WO/2018/129225A1
The present system is directed in one embodiment to a method of administration of a therapeutic composition for treatment, prevention and/or mitigation of the frequency and/or severity of impaired awareness of hypoglycemia (IAH). The met...  
WO/2018/129341A1
Presented herein, in certain embodiments, are nucleic acids and compositions for use in targeted gene editing.  
WO/2018/124749A1
The present invention relates to a novel peptide derived from the copine 7 protein and having both cell permeability and bone tissue regeneration ability, and to a use of the peptide. The peptide according to the present invention has ex...  
WO/2018/121702A1
A pharmaceutical composition of a GLP-1 analogue and a preparation method therefor. Specifically, the present invention relates to a pharmaceutical composition containing a GLP-1 receptor agonist and a salt of N-(8-(2-hydroxyphenylmethyl...  
WO/2018/121235A1
Provided is a BM23 peptide obtained by mutating and modifying BMP-2. The BM23 peptide has improved stability and duration of in vivo efficacy relative to BMP-2, can promote the differentiation of bone marrow mesenchymal stem cells into c...  
WO/2018/124277A1
[Problem] To provide a pharmaceutical composition that contains a fusion protein of an antibody and a lysosomal enzyme as an active ingredient and is stable enough to be distributed on the market. [Solution] A lyophilized preparation tha...  
WO/2018/124933A1
The invention relates to pharmacology and concerns a composition for preparing an anti-tumour agent that is a complex of bivalent platinum salts and alloferon peptide, and to pharmaceutical compositions containing said complexes. The inv...  
WO/2018/122278A1
The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a copolyamino acid bearing...  
WO/2018/122794A1
The present disclosure provides recombinant polypeptides, homodimeric and heterodimeric proteins comprising the recombinant polypeptides, nucleic acid molecules encoding the recombinant polypeptides, and vectors and host cells comprising...  
WO/2018/121457A1
Provided is a pharmaceutical application of a polypeptide in preventing or treating myocardial ischemia reperfusion injury-related diseases. The polypeptide can significantly reduce the myocardial infarct size in myocardial ischemia repe...  

Matches 1 - 50 out of 173,877